Development of decision-making considerations to support equitable patient selection in paediatric haemophilia trials

1 Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): 1–47. doi: 10.1111/j.1365-2516.2012.02909.x. SrivastavaA BrewerAK Mauser-BunschotenEP Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia Haemophilia 2013 19 1 1 47 10.1111/j.1365-2516.2012.02909.x 22776238 Open DOISearch in Google Scholar

2 Sulser E. A patient's perspective on hemophilia. Semin Hematol 2006; 43(2 Suppl 3): S13–6. doi: 10.1053/j.seminhematol.2006.02.005. SulserE A patient's perspective on hemophilia Semin Hematol 2006 43 2 Suppl 3 S13 6 10.1053/j.seminhematol.2006.02.005 16631822 Open DOISearch in Google Scholar

3 Jansen MO, Angelos P, Schrantz SJ, Donington JS, Madariaga MLL, Zakrison TL. Fair and equitable subject selection in concurrent COVID-19 clinical trials. J Med Ethics 2021; 47(1): 7–11. doi: 10.1136/medethics-2020-106590. JansenMO AngelosP SchrantzSJ DoningtonJS MadariagaMLL ZakrisonTL Fair and equitable subject selection in concurrent COVID-19 clinical trials J Med Ethics 2021 47 1 7 11 10.1136/medethics-2020-106590 755173833046590 Open DOISearch in Google Scholar

4 Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th edn. 2001. New York: Oxford University Press. BeauchampTL ChildressJF Principles of Biomedical Ethics 5th edn. 2001 New York Oxford University Press Search in Google Scholar

5 Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 2016; 35: 185–198. doi: 10.1200/EDBK_156686. UngerJM CookE TaiE BleyerA The role of clinical trial participation in cancer research: barriers, evidence, and strategies Am Soc Clin Oncol Educ Book 2016 35 185 198 10.1200/EDBK_156686 549511327249699 Open DOISearch in Google Scholar

6 Dobra R, Scott S, Davies JC, Simmonds NJ. Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials. J Cyst Fibros 2019; 18(5): e45–e46. doi: 10.1016/j.jcf.2019.04.008. DobraR ScottS DaviesJC SimmondsNJ Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials J Cyst Fibros 2019 18 5 e45 e46 10.1016/j.jcf.2019.04.008 31060801 Open DOISearch in Google Scholar

7 Weijer C. Selecting subjects for participation in clinical research: one sphere of justice. J Med Ethics 1999; 25(1): 31–36. doi: 10.1136/jme.25.1.31. WeijerC Selecting subjects for participation in clinical research: one sphere of justice J Med Ethics 1999 25 1 31 36 10.1136/jme.25.1.31 47916510070636 Open DOISearch in Google Scholar

8 MacKay D, Saylor KW. Four faces of fair subject selection. Am J Bioeth 2020; 20(2): 5–19. doi: 10.1080/15265161.2019.1701731. MacKayD SaylorKW Four faces of fair subject selection Am J Bioeth 2020 20 2 5 19 10.1080/15265161.2019.1701731 31990253 Open DOISearch in Google Scholar

9 Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283(20): 2701–2711. doi: 10.1001/jama.283.20.2701. EmanuelEJ WendlerD GradyC What makes clinical research ethical? JAMA 2000 283 20 2701 2711 10.1001/jama.283.20.2701 10819955 Open DOISearch in Google Scholar

10 Strassle C. Fair subject selection in cystic fibrosis trials. J Cyst Fibros 2019; 18(5): e47. doi: 10.1016/j.jcf.2019.05.019. StrassleC Fair subject selection in cystic fibrosis trials J Cyst Fibros 2019 18 5 e47 10.1016/j.jcf.2019.05.019 31196671 Open DOISearch in Google Scholar

11 MacKay D. Fair subject selection in clinical research: formal equality of opportunity. J Med Ethics 2016; 42(10): 672–677. doi: 10.1136/medethics-2015-103311. MacKayD Fair subject selection in clinical research: formal equality of opportunity J Med Ethics 2016 42 10 672 677 10.1136/medethics-2015-103311 27432910 Open DOISearch in Google Scholar

12 Gupta R, Morain SR. Ethical allocation of future COVID-19 vaccines. J Med Ethics 2020 Dec 17:medethics-2020-106850. doi: 10.1136/medethics-2020-106850. Epub ahead of print. GuptaR MorainSR Ethical allocation of future COVID-19 vaccines J Med Ethics 2020 Dec 17 medethics-2020-106850. 10.1136/medethics-2020-106850 Epub ahead of print 774749333335070 Open DOISearch in Google Scholar

13 Henn W. Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity. Vaccine 2020;38(34):5396–5397. doi:10.1016/j.vaccine.2020.06.058. HennW Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity Vaccine 2020 38 34 5396 5397 10.1016/j.vaccine.2020.06.058 730983132600909 Open DOISearch in Google Scholar

14 Rawlings A, Brandt L, Ferreres A, et al. Ethical considerations for allocation of scarce resources and alterations in surgical care during a pandemic. Surg Endosc 2021; 35(5): 2217–2222. doi: 10.1007/s00464-020-07629-x. RawlingsA BrandtL FerreresA Ethical considerations for allocation of scarce resources and alterations in surgical care during a pandemic Surg Endosc 2021 35 5 2217 2222 10.1007/s00464-020-07629-x 721685332399942 Open DOISearch in Google Scholar

15 Guidolin K, Catton J, Rubin B, et al. Ethical decision making during a healthcare crisis: a resource allocation framework and tool. J Med Ethics 2021; medethics-2021-107255. doi: 10.1136/medethics-2021-107255. GuidolinK CattonJ RubinB Ethical decision making during a healthcare crisis: a resource allocation framework and tool J Med Ethics 2021 medethics-2021-107255. 10.1136/medethics-2021-107255 814267534021059 Open DOISearch in Google Scholar

16 Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.TCPS 2. December 2018. Ottawa, ON: Secretariat on Responsible Conduct of Research. Available from https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2018.html (accessed 27 July 2021). Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.TCPS 2 December 2018 Ottawa, ON Secretariat on Responsible Conduct of Research Available from https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2018.html (accessed 27 July 2021). Search in Google Scholar

17 Wells JR, Gater A, Marshall C, Tritton T, Vashi P, Kessabi S. Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII). Patient 2019; 12(6): 611–619. doi: 10.1007/s40271-019-00374-x. WellsJR GaterA MarshallC TrittonT VashiP KessabiS Exploring the impact of infusion frequency in hemophilia A: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII) Patient 2019 12 6 611 619 10.1007/s40271-019-00374-x 688442931313270 Open DOISearch in Google Scholar

18 Iorio A, Marchesini E, Marcucci M, et al. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; (9): CD003429. doi: 10.1002/14651858.CD003429.pub4. IorioA MarchesiniE MarcucciM Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B Cochrane Database Syst Rev 2011 9 CD003429 10.1002/14651858.CD003429.pub4 21901684 Open DOISearch in Google Scholar

19 Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: Defining patient important outcomes. Res Pract Thromb Haemost 2019; 3(2): 184–192. doi: 10.1002/rth2.12195. KonkleBA SkinnerM IorioA Hemophilia trials in the twenty-first century: Defining patient important outcomes Res Pract Thromb Haemost 2019 3 2 184 192 10.1002/rth2.12195 646274031011702 Open DOISearch in Google Scholar

20 Zhou ZY, Riske B, Forsberg AD, et al. Self-reported barriers to hemophilia care in people with factor VIII deficiency. Am J Prev Med 2011; 41(6 Suppl 4): S346–S353. doi:10.1016/j.amepre.2011.09.003. ZhouZY RiskeB ForsbergAD Self-reported barriers to hemophilia care in people with factor VIII deficiency Am J Prev Med 2011 41 6 Suppl 4 S346 S353 10.1016/j.amepre.2011.09.003 22099357 Open DOISearch in Google Scholar

21 Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013 May 16; 4: 49–56. doi: 10.2147/JBM.S43734. SaxenaK Barriers and perceived limitations to early treatment of hemophilia J Blood Med 2013 May 16 4 49 56 10.2147/JBM.S43734 366013323700376 Open DOISearch in Google Scholar

22 Soares BMD, Simeoni LA, de Almeida KJQ, et al. Factors associated with compliance with the treatment protocol and mortality in adults with hemophilia. Patient Prefer Adherence 2020; 14: 2279–2285. doi:10.2147/PPA.S279401. SoaresBMD SimeoniLA de AlmeidaKJQ Factors associated with compliance with the treatment protocol and mortality in adults with hemophilia Patient Prefer Adherence 2020 14 2279 2285 10.2147/PPA.S279401 769164933262579 Open DOISearch in Google Scholar

23 Bodicoat DH, Routen AC, Willis A, et al. Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action. Trials 2021;22(1):880. doi:10.1186/s13063-021-05849-7. BodicoatDH RoutenAC WillisA Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action Trials 2021 22 1 880 10.1186/s13063-021-05849-7 864318434863265 Open DOISearch in Google Scholar